Therapeutic capabilities
Carrying endogenous therapeutic cargo
EviCure's advantages
Extracellular-vesicle advantages for targeted cancer therapy
The platform combines the natural properties of EVs with targeted-delivery potential and AI-controlled production.
Targeting ability
Homing ability to tumor sites
Robust and multi-faceted
Can be combined with exogenous therapies
Protecting cargo
Reduced degradation in body fluids and circulation
Non-immunogenic
Low MHC class I and II expression supporting off-the-shelf potential
Enhanced stability
Designed for stability in body fluids and practical handling
Prolonged PK/PD profile
Aims to improve on conventional delivery systems
Safety
Cellular sources with supporting pre-clinical and clinical safety experience
High batch reproducibility
AI-based, real-time controlled EV production process
Platform view
Built for targeted therapy
EviCure’s approach brings together endogenous therapeutic activity, cargo protection, tumor targeting and reproducible manufacturing within a single EV platform.
Learn about the platform